Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6585550rdf:typepubmed:Citationlld:pubmed
pubmed-article:6585550lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C0039667lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C1444754lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:6585550lifeskim:mentionsumls-concept:C0337112lld:lifeskim
pubmed-article:6585550pubmed:issue5lld:pubmed
pubmed-article:6585550pubmed:dateCreated1984-6-18lld:pubmed
pubmed-article:6585550pubmed:abstractTextn-Octyl, n-dodecyl, and n-hexadecyl alpha- and gamma-esters of methotrexate (MTX) were compared with the previously described alpha- and gamma-n-butyl esters and with MTX as inhibitors of dihydrofolate reductase (DHFR) and human leukemic lymphoblasts (CEM cells) in culture. The overall order of activity in both test systems was MTX greater than MTX gamma-esters greater than MTX alpha-esters. In the DHFR assay the activity of the alpha-esters followed the order C4 greater than C8 congruent to C12 greater than C16, whereas for the gamma-esters this order was C4 congruent to C8 greater than C12 greater than C16. On the other hand, the order of cytotoxic activity in culture in both series was C16 greater than C12 greater than C8 greater than C4. Increasing the alkyl chain length in the ester moiety therefore decreases DHFR affinity but increases cytotoxicity. The most potent member of the compounds tested was the gamma-n-hexadecyl ester, whose IC50 against CEM cells was 0.11 microM as compared with 0.025 microM for MTX. In a comparison of the effect of treatment with the gamma-n-hexadecyl ester (10(-5) M, 1 h) on DNA synthesis in CEM and CEM/MTX cells, the latter of which are 120-fold resistant to MTX by virtue of a transport defect, the ester produced only 4-fold less inhibition in the resistant line than in the parental line. These results suggest possible use of this compound or related derivatives in the treatment of MTX-resistant tumors with impaired transport.lld:pubmed
pubmed-article:6585550pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:languageenglld:pubmed
pubmed-article:6585550pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:citationSubsetIMlld:pubmed
pubmed-article:6585550pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6585550pubmed:statusMEDLINElld:pubmed
pubmed-article:6585550pubmed:monthMaylld:pubmed
pubmed-article:6585550pubmed:issn0022-2623lld:pubmed
pubmed-article:6585550pubmed:authorpubmed-author:LazarusHHlld:pubmed
pubmed-article:6585550pubmed:authorpubmed-author:YuC SCSlld:pubmed
pubmed-article:6585550pubmed:authorpubmed-author:RosowskyAAlld:pubmed
pubmed-article:6585550pubmed:authorpubmed-author:BeardsleyG...lld:pubmed
pubmed-article:6585550pubmed:authorpubmed-author:ForschR ARAlld:pubmed
pubmed-article:6585550pubmed:issnTypePrintlld:pubmed
pubmed-article:6585550pubmed:volume27lld:pubmed
pubmed-article:6585550pubmed:ownerNLMlld:pubmed
pubmed-article:6585550pubmed:authorsCompleteYlld:pubmed
pubmed-article:6585550pubmed:pagination605-9lld:pubmed
pubmed-article:6585550pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:meshHeadingpubmed-meshheading:6585550-...lld:pubmed
pubmed-article:6585550pubmed:year1984lld:pubmed
pubmed-article:6585550pubmed:articleTitleMethotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters.lld:pubmed
pubmed-article:6585550pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6585550pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6585550pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:6585550lld:chembl